Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2018-07
  • Cell Counting Kit-8 (CCK-8): Precision Cell Viability and...

    2025-11-22

    Cell Counting Kit-8 (CCK-8): Precision Cell Viability and Cytotoxicity Measurement

    Executive Summary: The Cell Counting Kit-8 (CCK-8) utilizes WST-8, a water-soluble tetrazolium salt, to quantitatively assess cell viability via mitochondrial dehydrogenase activity (Wang et al., 2025). The resulting formazan dye is directly proportional to the number of viable cells, providing a non-radioactive, sensitive, and high-throughput solution (APExBIO product page). CCK-8 outperforms traditional MTT/XTT/MTS assays in terms of workflow simplicity and sensitivity (Advanced Insights article). The kit is widely used in cancer research, metabolic studies, and drug screening, including recent applications in gastric cancer metabolism (Wang et al., 2025). APExBIO's CCK-8 (K1018) is validated and cited in peer-reviewed research, supporting robust, reproducible results in vitro.

    Biological Rationale

    The Cell Counting Kit-8 (CCK-8) addresses the need for accurate, quantitative cell viability assessment in biomedical research. Cellular viability and proliferation assays are foundational for evaluating drug efficacy, cytotoxicity, and metabolic state (Wang et al., 2025). The hallmark of many diseases, including cancer and neurodegeneration, is altered cellular metabolic activity and proliferation rate (Theranostics). Traditional methods such as MTT and XTT assays have limitations in solubility, sensitivity, and workflow complexity. The CCK-8 kit, by leveraging WST-8 chemistry, provides a more sensitive, less toxic, and easily quantifiable solution ( Cell Counting Kit-8 (CCK-8)). This capability directly supports research into glycolytic reprogramming and mitochondrial function, as highlighted in studies of gastric tumorigenesis (Wang et al., 2025).

    Mechanism of Action of Cell Counting Kit-8 (CCK-8)

    CCK-8 employs WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt), a water-soluble tetrazolium salt. In metabolically active cells, intracellular dehydrogenases reduce WST-8 to a water-soluble orange formazan dye (Advanced Insights article). The amount of formazan produced is directly proportional to the number of living cells. Unlike MTT, the formazan product does not require solubilization, streamlining the workflow. The assay is non-radioactive and compatible with standard 96-well or 384-well microplate readers at 450 nm absorbance (APExBIO product page). This mechanism enables high-throughput, quantitative assessment of cell viability, proliferation, and cytotoxicity.

    Evidence & Benchmarks

    • CCK-8 demonstrated linear correlation (R² > 0.99) between absorbance at 450 nm and viable cell number in gastric cancer cell lines across a range of 1x103 to 1x105 cells/well (Wang et al., 2025).
    • WST-8 used in CCK-8 showed higher sensitivity and lower cytotoxicity than MTT or XTT, reducing cell stress during repeated measurements (Advanced Insights article).
    • CCK-8 protocol enabled assessment of glycolytic activity shifts in response to targeted metabolic interventions in gastric cancer models (Wang et al., 2025).
    • CCK-8's formazan output is water-soluble, eliminating the need for DMSO solubilization required in MTT assays, improving throughput and accuracy (APExBIO product page).
    • Peer-reviewed studies confirm CCK-8's compatibility with drug screening, toxicology, and metabolic flux measurements in diverse cell types (Sensitive Cell Viability article).

    Applications, Limits & Misconceptions

    CCK-8 is extensively used in cancer research, neurodegenerative disease studies, cellular metabolic activity assessment, and drug cytotoxicity screening. The kit is particularly valuable in settings requiring repeated or high-throughput viability measurements, such as phenotypic drug screening and metabolic flux analysis (Optimizing Cell Viability Assays). CCK-8 is also applied in regenerative medicine and disease modeling, as well as in studies investigating mitochondrial dehydrogenase activity and the Warburg effect in cancer ( Wang et al., 2025).

    Common Pitfalls or Misconceptions

    • Does not distinguish between cell death modalities: CCK-8 measures viable cell number but cannot differentiate apoptosis from necrosis or autophagy-induced death (Sensitive Cell Viability article).
    • Assay interference by reducing agents: Compounds with intrinsic redox activity (e.g., vitamin C, DTT) may produce false-positive results.
    • Not suitable for non-adherent cell types without optimization: Suspension cells may require additional steps to ensure accurate quantification.
    • Readout dependence on metabolic activity: Quiescent or metabolically suppressed cells may register as non-viable, even if alive.
    • Plate edge effects and evaporation: Variations in well volume or temperature can affect results; controls are required (Optimizing Cell Viability Assays).

    This article extends the discussion in Optimizing Cell Viability Assays with Cell Counting Kit-8 by providing detailed mechanistic and benchmark data for CCK-8 in cancer and metabolic research contexts. It also clarifies advanced applications overviews presented in Cell Counting Kit-8 (CCK-8): Advanced Insights into WST-8, focusing on evidence-based performance comparisons.

    Workflow Integration & Parameters

    APExBIO's CCK-8 (K1018) is delivered ready-to-use and is compatible with 96-well and 384-well formats. Typical protocol:

    1. Seed 1x103-1x105 cells/well in appropriate culture medium. Incubate at 37°C, 5% CO2 for 12–24 h.
    2. Add 10 µL of CCK-8 reagent per 100 µL medium per well.
    3. Incubate for 1–4 h (time optimized per cell type and density).
    4. Measure absorbance at 450 nm using a microplate reader.

    Key parameters:

    • Dynamic range: Linear from 1x103 to 1x105 cells/well.
    • Incubation: Shorter times for highly metabolic cells, longer for slow-growing lines.
    • No solubilization step required—results are direct-read.
    • Controls: Include blank wells (no cells), negative controls (dead cells), and positive controls (untreated cells) per plate.

    For troubleshooting and advanced protocol optimization, see Cell Counting Kit-8: Precision Cell Viability Measurement, which provides detailed guidance on maximizing data reliability across diverse applications.

    Conclusion & Outlook

    The Cell Counting Kit-8 (CCK-8) from APExBIO (K1018) establishes a gold standard for sensitive, high-throughput cell viability and cytotoxicity assays. Its water-soluble, low-toxicity WST-8 chemistry streamlines workflows and enables reproducible results in cancer research, drug screening, and metabolic studies (Wang et al., 2025). Ongoing innovations in assay integration and data analysis—paired with rigorous protocol optimization—ensure that CCK-8 will remain a pivotal tool for translational research targeting cellular metabolism and disease modeling (Redefining Translational Research article).